2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Autor: Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen J, Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis E, Fauchier, Laurent, Filippatos, Gerasimos, Kalman, Jonathan M, La Meir, Mark, Lane, Deirdre A, Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory Y H, Pinto, Fausto J, Thomas, G Neil, Valgimigli, Marco, Van Gelder, Isabelle C, Van Putte, Bart P, Watkins, Caroline L, Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, A John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry J G M, Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Fitzsimons, Donna, Folliguet, Thierry, Gale, Chris P, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo A, Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil S, Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia V, Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto F E, Petersen, Steffen E, Piccini, Jonathan P, Popescu, Bogdan A, Pürerfellner, Helmut, Richter, Dimitrios J, Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate B, Simpson, Iain A, Shlyakhto, Evgeny, Sinner, Moritz F, Steffel, Jan, Sousa-Uva, Miguel, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian M, Neil Thomas, G
Přispěvatelé: CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cardiovascular Centre (CVC), Surgical clinical sciences, Cardiac Surgery
Rok vydání: 2021
Předmět:
left atrial ablation
left atrial appendage occlusion
AF surgery
medicine.medical_treatment
[SDV]Life Sciences [q-bio]
Management of atrial fibrillation
030204 cardiovascular system & hematology
Cardioversion
VITAMIN-K ANTAGONIST
surgery
chemistry.chemical_compound
0302 clinical medicine
cardioversion
Edoxaban
QUALITY-OF-LIFE
antiarrhythmic drugs
OBSTRUCTIVE SLEEP-APNEA
catheter ablation
RADIOFREQUENCY CATHETER ABLATION
Medicine
atrial fibrillation
030212 general & internal medicine
anticoagulation
reproductive and urinary physiology
ComputingMilieux_MISCELLANEOUS
pulmonary vein isolation
0303 health sciences
rhythm control
EACTS
HEART RHYTHM SOCIETY
recommendations
Atrial fibrillation
General Medicine
non-Vitamin K antagonist oral anticoagulants
Vitamin K antagonist
PULMONARY-VEIN ISOLATION
stroke
3. Good health
2020 ESC Guidelines
Dronedarone
vitamin K antagonists
Cardiothoracic surgery
Cardio-Thoracic Surgery
embryonic structures
DIRECT ORAL ANTICOAGULANTS
cardiovascular system
Cardiology
Dose reduction
biological phenomena
cell phenomena
and immunity
Cardiology and Cardiovascular Medicine
medicine.drug
Quinidine
medicine.medical_specialty
medicine.drug_class
non-vitamin K antagonist oral anticoagulants
PERCUTANEOUS CORONARY INTERVENTION
Renal function
macromolecular substances
ABC pathway
Guidelines
rate control
screening
upstream therapy
Vitamin K antagonists
B700
03 medical and health sciences
Internal medicine
Diseases of the circulatory (Cardiovascular) system
cardiovascular diseases
030304 developmental biology
urogenital system
business.industry
medicine.disease
TRANSIENT ISCHEMIC ATTACK
ANTIARRHYTHMIC-DRUG-THERAPY
chemistry
030228 respiratory system
Concomitant
RC666-701
business
Zdroj: European Heart Journal
European Heart Journal, Oxford University Press (OUP): Policy B, 2020, ⟨10.1093/eurheartj/ehaa612⟩
Российский кардиологический журнал, Vol 26, Iss 9 (2021)
European Heart Journal, 42(5), 373-498. Oxford University Press
European Heart Journal, 42(5), 373-498. OXFORD UNIV PRESS
ISSN: 2618-7620
1560-4071
0195-668X
1522-9645
Popis: Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight
Databáze: OpenAIRE
Externí odkaz: